NuPathe’s price cut shows slow biotech IPO recovery

Conshohocken, PA-based NuPathe has cuts its IPO price to just $10 a share, the company announced today. NuPathe was hoping to raise between $14 and $16 per share for a total of $75 million. The developer still plans to offer 5 million shares. NuPathe's has a migraine treatment called Zelrix which has completed Phase III testing. The trial showed that migraine symptoms like pain, nausea and sensitivity to light and sound, significantly improved two hours after applying...

NuPathe plans to raise $75M with IPO

Conshohocken, PA-based NuPathe, which is developing a transdermal patch version of the popular migraine treatment Imitrex, has set the terms of its proposed IPO. NuPathe will offer 5 million common shares at $14 and $16 per share, giving the company a market cap of $255 million. The developer hopes to raise up to $75 million with the offering. NuPathe will trade on the NASDAQ under ticker symbol PATH. NuPathe's migraine treatment, called Zelrix, has completed Phase III...

NuPathe plots $86M IPO

Yet another biotech company has announced plans to file an IPO. Conshohocken, PA-based NuPathe, which is developing a transdermal patch to treat migraines, hopes to raise $86.3 million, according to an SEC filing. The company is applying to list its common stock on NASDAQ under the symbol PATH. NuPathe's most advanced product candidate, Zelrix, is a single-use patch that delivers the commonly prescribed migraine drug sumatriptan. The company completed a Phase III trial for Zelrix in July...